Logo image of NVAX

NOVAVAX INC (NVAX) Stock Fundamental Analysis

NASDAQ:NVAX - Nasdaq - US6700024010 - Common Stock - Currency: USD

7.29  +0.18 (+2.53%)

After market: 7.2969 +0.01 (+0.09%)

Fundamental Rating

4

NVAX gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 561 industry peers in the Biotechnology industry. NVAX has a medium profitability rating, but doesn't score so well on its financial health evaluation. NVAX is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

4

1. Profitability

1.1 Basic Checks

In the past year NVAX was profitable.
NVAX had a negative operating cash flow in the past year.
NVAX had negative earnings in each of the past 5 years.
In the past 5 years NVAX reported 4 times negative operating cash flow.
NVAX Yearly Net Income VS EBIT VS OCF VS FCFNVAX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500M -1B -1.5B

1.2 Ratios

The Return On Assets of NVAX (37.02%) is better than 99.29% of its industry peers.
With an excellent Return On Invested Capital value of 38.36%, NVAX belongs to the best of the industry, outperforming 99.64% of the companies in the same industry.
Industry RankSector Rank
ROA 37.02%
ROE N/A
ROIC 38.36%
ROA(3y)-23.82%
ROA(5y)-33.12%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NVAX Yearly ROA, ROE, ROICNVAX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K 2K 3K 4K 5K

1.3 Margins

NVAX's Profit Margin of 38.14% is amongst the best of the industry. NVAX outperforms 98.40% of its industry peers.
The Operating Margin of NVAX (33.69%) is better than 98.57% of its industry peers.
NVAX has a Gross Margin of 87.52%. This is amongst the best in the industry. NVAX outperforms 89.84% of its industry peers.
Industry RankSector Rank
OM 33.69%
PM (TTM) 38.14%
GM 87.52%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NVAX Yearly Profit, Operating, Gross MarginsNVAX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

3

2. Health

2.1 Basic Checks

NVAX has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
NVAX has more shares outstanding than it did 1 year ago.
NVAX has more shares outstanding than it did 5 years ago.
The debt/assets ratio for NVAX is higher compared to a year ago.
NVAX Yearly Shares OutstandingNVAX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
NVAX Yearly Total Debt VS Total AssetsNVAX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B

2.2 Solvency

NVAX has an Altman-Z score of -1.89. This is a bad value and indicates that NVAX is not financially healthy and even has some risk of bankruptcy.
NVAX's Altman-Z score of -1.89 is in line compared to the rest of the industry. NVAX outperforms 55.79% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -1.89
ROIC/WACC3.79
WACC10.11%
NVAX Yearly LT Debt VS Equity VS FCFNVAX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M -400M 600M -600M

2.3 Liquidity

A Current Ratio of 2.06 indicates that NVAX has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 2.06, NVAX is doing worse than 74.51% of the companies in the same industry.
NVAX has a Quick Ratio of 2.03. This indicates that NVAX is financially healthy and has no problem in meeting its short term obligations.
NVAX's Quick ratio of 2.03 is on the low side compared to the rest of the industry. NVAX is outperformed by 72.91% of its industry peers.
Industry RankSector Rank
Current Ratio 2.06
Quick Ratio 2.03
NVAX Yearly Current Assets VS Current LiabilitesNVAX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

5

3. Growth

3.1 Past

NVAX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 173.50%, which is quite impressive.
NVAX shows a strong growth in Revenue. In the last year, the Revenue has grown by 25.92%.
NVAX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 105.31% yearly.
EPS 1Y (TTM)173.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%379.05%
Revenue 1Y (TTM)25.92%
Revenue growth 3Y-15.89%
Revenue growth 5Y105.31%
Sales Q2Q%610.3%

3.2 Future

The Earnings Per Share is expected to grow by 19.82% on average over the next years. This is quite good.
The Revenue is expected to decrease by -8.27% on average over the next years.
EPS Next Y251.87%
EPS Next 2Y49.43%
EPS Next 3Y21.86%
EPS Next 5Y19.82%
Revenue Next Year36.71%
Revenue Next 2Y-12.41%
Revenue Next 3Y-26.24%
Revenue Next 5Y-8.27%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
NVAX Yearly Revenue VS EstimatesNVAX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B 2B
NVAX Yearly EPS VS EstimatesNVAX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -5 -10 -15 -20

6

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 3.13 indicates a rather cheap valuation of NVAX.
Compared to the rest of the industry, the Price/Earnings ratio of NVAX indicates a rather cheap valuation: NVAX is cheaper than 99.29% of the companies listed in the same industry.
NVAX's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 25.91.
A Price/Forward Earnings ratio of 18.97 indicates a rather expensive valuation of NVAX.
NVAX's Price/Forward Earnings ratio is rather cheap when compared to the industry. NVAX is cheaper than 92.51% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 21.85. NVAX is around the same levels.
Industry RankSector Rank
PE 3.13
Fwd PE 18.97
NVAX Price Earnings VS Forward Price EarningsNVAX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, NVAX is valued cheaply inside the industry as 99.47% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 0.39
NVAX Per share dataNVAX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as NVAX's earnings are expected to grow with 21.86% in the coming years.
PEG (NY)0.01
PEG (5Y)N/A
EPS Next 2Y49.43%
EPS Next 3Y21.86%

0

5. Dividend

5.1 Amount

NVAX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

NOVAVAX INC

NASDAQ:NVAX (5/22/2025, 8:00:01 PM)

After market: 7.2969 +0.01 (+0.09%)

7.29

+0.18 (+2.53%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08 2025-05-08/bmo
Earnings (Next)08-06 2025-08-06
Inst Owners60.5%
Inst Owner Change-3.77%
Ins Owners0.35%
Ins Owner Change22.03%
Market Cap1.18B
Analysts78.46
Price Target17 (133.2%)
Short Float %28.64%
Short Ratio6.45
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)124.28%
Min EPS beat(2)-58.31%
Max EPS beat(2)306.88%
EPS beat(4)2
Avg EPS beat(4)53.44%
Min EPS beat(4)-58.31%
Max EPS beat(4)306.88%
EPS beat(8)5
Avg EPS beat(8)21.96%
EPS beat(12)6
Avg EPS beat(12)-34.55%
EPS beat(16)6
Avg EPS beat(16)-60.38%
Revenue beat(2)2
Avg Revenue beat(2)46.34%
Min Revenue beat(2)2.61%
Max Revenue beat(2)90.08%
Revenue beat(4)3
Avg Revenue beat(4)23.46%
Min Revenue beat(4)-11.17%
Max Revenue beat(4)90.08%
Revenue beat(8)5
Avg Revenue beat(8)20.39%
Revenue beat(12)6
Avg Revenue beat(12)7.16%
Revenue beat(16)6
Avg Revenue beat(16)-2.44%
PT rev (1m)-5.66%
PT rev (3m)-4.21%
EPS NQ rev (1m)-123.23%
EPS NQ rev (3m)-107.08%
EPS NY rev (1m)216.99%
EPS NY rev (3m)1159.83%
Revenue NQ rev (1m)-4.95%
Revenue NQ rev (3m)-30.59%
Revenue NY rev (1m)38.53%
Revenue NY rev (3m)68.02%
Valuation
Industry RankSector Rank
PE 3.13
Fwd PE 18.97
P/S 0.94
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA 0.39
EPS(TTM)2.33
EY31.96%
EPS(NY)0.38
Fwd EY5.27%
FCF(TTM)-1.21
FCFYN/A
OCF(TTM)-1.17
OCFYN/A
SpS7.75
BVpS-0.47
TBVpS-1.16
PEG (NY)0.01
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 37.02%
ROE N/A
ROCE 48.55%
ROIC 38.36%
ROICexc 239.72%
ROICexgc 1222.82%
OM 33.69%
PM (TTM) 38.14%
GM 87.52%
FCFM N/A
ROA(3y)-23.82%
ROA(5y)-33.12%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.97
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA 0.48
Cap/Depr 16.56%
Cap/Sales 0.59%
Interest Coverage 22.06
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.06
Quick Ratio 2.03
Altman-Z -1.89
F-Score5
WACC10.11%
ROIC/WACC3.79
Cap/Depr(3y)158.98%
Cap/Depr(5y)408.8%
Cap/Sales(3y)4.02%
Cap/Sales(5y)5.71%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)173.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%379.05%
EPS Next Y251.87%
EPS Next 2Y49.43%
EPS Next 3Y21.86%
EPS Next 5Y19.82%
Revenue 1Y (TTM)25.92%
Revenue growth 3Y-15.89%
Revenue growth 5Y105.31%
Sales Q2Q%610.3%
Revenue Next Year36.71%
Revenue Next 2Y-12.41%
Revenue Next 3Y-26.24%
Revenue Next 5Y-8.27%
EBIT growth 1Y211.83%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year94.57%
EBIT Next 3Y13.97%
EBIT Next 5YN/A
FCF growth 1Y73.75%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y71.02%
OCF growth 3YN/A
OCF growth 5YN/A